Results 141 to 150 of about 66,449 (275)

Aliphatic Poly(Carbonate)s with Acid Responsive Release Mechanisms for Micellar Anti‐Tumor Drug Delivery

Macromolecular Rapid Communications, EarlyView.
Micellar systems based on biodegradable aliphatic polycarbonates and acid‐responsive triggers enhance drug solubility, stability, and tumor‐selective release. This review covers micelles with acid‐cleavable drug linkages and those that disassemble via acid‐sensitive functionalities.
Adrian V. Hauck, Lutz Nuhn
wiley   +1 more source

Gemcitabine Overcomes Erlotinib Resistance in EGFR-Overexpressing Cancer Cells through Downregulation of Akt

Journal of Cancer, 2011
A phase III clinical trial showed gemcitabine chemotherapy combined with epidermal growth factor receptor (EGFR) tyrosine kinase inhibitor erlotinib significantly improved overall survival in patients with advanced pancreatic cancer.
Chandra Bartholomeusz, Fumiyuki Yamasaki, Hitomi Saso, Kaoru Kurisu, Gabriel N. Hortobagyi, Naoto T. Ueno
doaj  

CRISPR‐Based Gene Dependency Screens Reveal Mechanism of BRAF Inhibitor Resistance in Anaplastic Thyroid Cancer

Molecular Carcinogenesis, EarlyView.
ABSTRACT Anaplastic thyroid cancer (ATC) is the most aggressive form of thyroid cancer. Despite recent advances in treating BRAFV600E‐driven ATC, therapy resistance remains a significant challenge, often resulting in disease progression and death.
Shawn Noronha, Yue Liu, Gaga Geneti, Haojian Li, Xiaolin Wu, David Sun, Vaibhavi Gujar, Takashi Furusawa, Alexei Lobanov, Maggie Cam, Lipika R. Pal, Nishanth U. Nair, Chi‐Ping Day, Eytan Ruppin, Chandrayee Ghosh, Jiangnan Hu, Bhavishya Ramamoorthy, Suresh Kumar, Thorkell Andresson, King Chan, Maura O'Neill, Raj Chari, Yves Pommier, Jaydira Del Rivero, Urbain Weyemi, Electron Kebebew, Myriem Boufraqech   +26 more
wiley   +1 more source

Addressing the distressing: Pancreatic enzyme replacement therapy mitigates abdominal symptoms and weight loss during chemotherapy for advanced pancreatic cancer: A prospective study

Nutrition in Clinical Practice, EarlyView.
Abstract Background Pancreatic enzyme insufficiency (PEI) contributes to symptom burden and malnutrition in advanced pancreatic cancer (aPC). We aimed to evaluate the impact of pancreatic enzyme replacement therapy (PERT) on symptom burden and weight during chemotherapy.
Pamela N. Klassen, Christina A. Kim, Jessica Kasnik, Michael B. Sawyer, Sunita Ghosh, Vickie Baracos, Vera C. Mazurak   +6 more
wiley   +1 more source

PPAR-alpha: a novel target in pancreatic cancer [PDF]

, 2015
Background: Current targeted therapies in pancreatic cancer have been ineffective. The tumor stroma, including intra- and peri-tumoral inflammation and fibrosis, is increasingly implicated in pancreatic cancer.
Hua, Alexander Mach
core   +1 more source

Whole‐transcriptome sequencing analyses identified exosomal circular RNAs in the plasma of pancreatic cancer patients as novel blood‐based biomarkers of disease

VIEW, EarlyView.
Pancreatic cancer (PaCa) has a poor prognosis, with low resection rates and high relapse rates, highlighting the urgent need for novel diagnostic biomarkers. Here, we performed whole‐transcriptome sequencing of plasma‐derived exosomes from PaCa patients and identified several differentially expressed circular RNAs (circRNAs).
Xiaomeng He, Yang Di, Lixiang Sun, Zhirong Wu, Mengting Luo, Xin Zhang, Huaqin Sun, Wanli Xu, Wenchuan Wu, Boheng Zhang, Jin Wang   +10 more
wiley   +1 more source

Inhibition of PHF1 promotes ferroptosis via IRES‐dependent Snail translation regulation in pancreatic ductal adenocarcinoma

VIEW, EarlyView.
PHF1 is a known epigenetic regulator involved in transcriptional silencing in cancer. In this study, we identified PHF1 as an oncogene that promotes PDAC progression and demonstrated that its inhibition induces ferroptosis. Mechanistically, PHF1 physically interacts with the FBL/NOP56/NOP58 snoRNP complex to enhance the IRES‐dependent translation of ...
Yujiao Xie, Shan Jin, Yao Zhan, Tiantian Du, Yaqi Dong, Peilong Li, Xiaoshi Zhang, Qiuchen Qi, Jie Gao, Chuanxin Wang   +9 more
wiley   +1 more source

EGR1 mediates MDR1 transcriptional activity regulating gemcitabine resistance in pancreatic cancer

BMC Cancer
Background Gemcitabine is a cornerstone drug for the treatment of all stages of pancreatic cancer and can prolong the survival of patients with pancreatic cancer, but resistance to gemcitabine in pancreatic cancer patients hinders its efficacy.
Zhe Yang, Feiran Chen, Dafu Wei, Fengping Chen, Haixing Jiang, Shanyu Qin   +5 more
doaj   +1 more source

Combination of hydroxyurea and tranilast suppresses gemcitabine resistance induced by ribonucleotide reductase M1 in gemcitabine-resistant cells

, 2021
鹿児島大学
openaire   +1 more source

RGDV-modified gemcitabine: a nano-medicine capable of prolonging half-life, overcoming resistance and eliminating bone marrow toxicity of gemcitabine

International Journal of Nanomedicine, 2019
Wenchao Liu1,2, Yujia Mao1,2, Xiaoyi Zhang1,2, Yaonan Wang1,2, Jianhui Wu1,2, Shurui Zhao1,2, Shiqi Peng1,2, Ming Zhao1–3 1Beijing Area Major Laboratory of Peptide and Small Molecular Drugs, Department of Medicinal Chemistry, School of ...
Liu W, Mao Y, Zhang X, Wang Y, Wu J, Zhao S, Peng S, Zhao M   +7 more
doaj